龍溪股份(600592.SH):涉及漳州藍田開發區工業用地等已移交公司使用
格隆匯8月13日丨龍溪股份(600592.SH)公佈,公司七屆十八次董事會及2019年年度股東大會審議通過,公司擬以自有資金1.37億元人民幣,向福建力佳股份有限公司(以下簡稱“力佳股份”)購買位於漳州藍田開發區內面積129,516.57㎡(約194.28畝)工業用地的使用權、該地塊內總建築面積73,729.86㎡的工業廠房、附屬建築物及生產機器設備60台(套)。公司與力佳股份於2020年6月28日簽署了《資產轉讓協議》。
日前,交易雙方已完成上述不動產權變更登記手續,公司於2020年8月12日取得上述土地、房產的不動產權證,本次交易購買的資產已移交公司使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.